CD354 (TREM-1) Monoclonal Antibody (TR3MBL1), eFluor™ 660, eBioscience™, Invitrogen™

Description

• Description: The TR3MBL1 monoclonal antibody recognizes mouse CD354 (also known as TREM-1), a 30-kDa glycosylated member of the Ig superfamily
• CD354 is expressed on the cell surface of myeloid cells such as neutrophils, monocytes, dendritic cells, some macrophages, platelets, and megakaryocytes
• Outside the immune system, CD354 is expressed on hepatocytes, osteoclasts, and microglia
• CD354 also exists as a soluble receptor (sTREM-1) that arises from proteolytic cleavage of the membrane-bound receptor by matrix metalloproteases
• CD354 plays a critical role in the innate immune response to bacterial and fungal infection by triggering the release of pro-inflammatory chemokines and cytokines
• The cell surface receptor associates constitutively with the ITAM-containing adaptor protein DAP12 to activate the MAPK and NFkB signaling pathways
• Finally, levels of the soluble receptor are increased in several inflammatory diseases, including sepsis, asthma, and inflammatory bowel disease, making this receptor a valuable diagnostic biomarker
• Applications Reported: This TR3MBL1 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This TR3MBL1 antibody has been tested by flow cytometric analysis of mouse peripheral blood cells
• This can be used at less than or equal to 0.125 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• TREM1 (triggering receptor expressed on myeloid cells 1) is a receptor belonging to the Ig superfamily that amplifies neutrophil and monocyte-mediated inflammatory responses triggered by bacterial and fungal infections by stimulating release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers
• It is thought that TREM1 other related TREM proteins such as TREM2 act to modulate the inflammatory response
• TREM1 has also been linked to inflammatory bowel disease resulting in enhanced production of TNF, IL-6, IL-8, and MCP-1.